IL1A and COVID-19: What is evident from this study is that IL1 pathway seems to play a pivotal role on the risk of mortality in severe COVID-19 patients, as previously postulated (Attur et al., 2023), and that genetic regulation of these genes could have an impact on the efficacy of Tocilizumab in terms of mortality.